Two Eli Lilly manufacturing plants in Indiana are getting a $5.3 billion boost to increase production of Zepbound and Mounjaro, the company said May 24.
The investment "represents the single largest investment in synthetic medicine [active pharmaceutical ingredient] manufacturing in U.S. history," Eli Lilly's chair and CEO David Ricks said in a news release.
Leaders of the manufacturing sites in Lebanon, Ind., will hire 200 full-time workers to help increase production. Mounjaro is approved for Type 2 diabetes and Zepbound is indicated for chronic weight management. Eli Lilly is also eyeing a Zepbound label expansion after finding positive results in a sleep apnea trial.
The announcement raises the company's total investment in the Lebanon site from $3.7 billion to $9 billion.